PURPLE BIOTECH LTD. — Regulatory Filings 2016

6-K 1 v441448_6k.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

W ashington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of June 2016

Commission File Number: 001-37643

KITOV PHARMACEUTICALS HOLDINGS LTD.

(Translation of registrant's name into English)

One Azrieli Center, Round Tower, 23 rd Floor,

Tel Aviv 6701101, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Field: Page; Sequence: 1

Field: /Page

On June 1, 2016, Kitov Pharmaceuticals Holdings Ltd. (the “Company” or the “Registrant”) published a report in Hebrew with the Israel Securities Authority and the Tel Aviv Stock Exchange containing an updated Registry of Securities Holders of the Company as of May 31, 2016.

Below is a summary translation of the updated Registry of Securities Holders of the Company as of May 31, 2016:

(1) 21 of such Ordinary Shares are dormant shares held in treasury. The 79,479,060 issued and outstanding Ordinary Shares would be represented by 3,973,953 of our American Depositary Shares (ADSs), as each of our ADSs represents 20 of our Ordinary Shares.

(2) Each Series 6/14 option is exercisable into 0.07692 Ordinary Shares of the Company. The aggregate number of Series 6/14 options exercise Ordinary Shares is 91,455. Such number of Ordinary Shares would be represented by 4,572.75 of our ADSs.

(3) Each Series 7/14 option is exercisable into 0.07692 Ordinary Shares of the Company. The aggregate number of Series 7/14 options exercise Ordinary Shares is 46,152. Such number of Ordinary Shares would be represented by 2,307.6 of our ADSs.

(4) Each Series 5/15 option is exercisable into 1 Ordinary Share of the Company. The 44,786 options exercise Ordinary Shares would be represented by 2,239.3 of our ADSs.

(5) Each Series 9/15 option is exercisable into 1 Ordinary Share of the Company. The 1,720,000 options exercise Ordinary Shares would be represented by 86,000 of our ADSs.

(6) Each Underwriter Warrant is exercisable into one ADS of the Company. The aggregate number of Kitov Underwriter Warrant exercise ADSs is 157,945, which would represent 3,158,900 of our Ordinary Shares.

(7) Each 2016 Equity-Based Incentive Plan option is exercisable into 1 Ordinary Share of the Company. The 1,323,886 options exercise Ordinary Shares would be represented by 66,194.3 of our ADSs.

(8) Each Nasdaq Listed Warrant is exercisable into one ADS of the Company. The aggregate number of Kitov Nasdaq Listed Warrant exercise ADSs is 3,306,257, which would represent 66,125,140 of our Ordinary Shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Field: Page; Sequence: 2; Options: Last

Field: /Page